The intersection of cardiovascular disease (CVD) and cancer presents a significant clinical dilemma, as both conditions are leading causes of morbidity and mortality globally. Understanding their reciprocal relationship is essential for optimising patient management and improving long-term outcomes. The immediate takeaway is that clinicians must consider the implications of one disease on the other, both in terms of shared risk factors and treatment-related toxicities.
Cardiovascular disease and cancer are complex, multifactorial conditions that frequently coexist in the same patient population. This co-occurrence is not merely coincidental but reflects shared underlying risk factors, including advanced age, obesity, diabetes, hypertension, dyslipidaemia, and inflammation.1 Furthermore, many cancer therapies, while effective in disease control, can exert significant cardiotoxic effects, leading to new or exacerbated cardiovascular complications.2 Conversely, pre-existing cardiovascular conditions can influence cancer treatment decisions and outcomes, sometimes necessitating modifications to standard oncological regimens.3
The Reciprocal Relationship and Clinical Implications
The relationship between CVD and cancer is increasingly understood as reciprocal. Patients with cancer face an elevated risk of developing cardiovascular complications, including heart failure, arrhythmias, myocardial infarction, and thromboembolic events.2 For example, anthracyclines, a class of chemotherapy agents, are known to cause dose-dependent left ventricular dysfunction and heart failure.4 Trastuzumab, a monoclonal antibody used in HER2-positive breast cancer, can also induce cardiac dysfunction, particularly when combined with anthracyclines.5 Radiation therapy to the chest can lead to pericardial disease, valvular heart disease, coronary artery disease, and cardiomyopathy, with effects often manifesting years after treatment.6
Beyond direct cardiotoxicity, cancer itself can induce a pro-inflammatory state and hypercoagulability, contributing to an increased risk of arterial and venous thromboembolism.7 This heightened thrombotic risk is particularly pronounced in certain cancer types, such as pancreatic and lung cancer, and during specific treatment phases.8
Conversely, patients with pre-existing cardiovascular disease may experience worse cancer outcomes. The presence of conditions like heart failure or severe coronary artery disease can limit the use of potentially curative or life-prolonging cancer therapies due to concerns about exacerbating cardiac function or increasing treatment-related mortality.3 This can lead to dose reductions, treatment delays, or the selection of less effective alternative therapies, potentially compromising oncological efficacy.9 Moreover, the systemic inflammation and metabolic derangements associated with chronic CVD may also influence tumour progression and response to treatment.10
The management of patients with both conditions requires a coordinated, multidisciplinary approach. Pre-treatment cardiovascular risk assessment is crucial for identifying patients at high risk of cardiotoxicity.11 During cancer treatment, regular cardiovascular monitoring, including echocardiography and biomarker assessment, can facilitate early detection and management of cardiac dysfunction.12 Pharmacological interventions, such as beta-blockers or ACE inhibitors, may be considered in certain high-risk populations to mitigate cardiotoxicity.13 Post-treatment, long-term surveillance for cardiovascular complications is essential, as some cardiotoxic effects can manifest years after cancer therapy completion.6
The integration of cardio-oncology services aims to bridge the gap between cardiology and oncology, ensuring that patients receive optimal care for both conditions. This collaborative model supports personalised treatment strategies that balance oncological efficacy with cardiovascular safety, ultimately striving to improve overall survival and quality of life for patients facing this dual burden.14
The increasing recognition of the reciprocal relationship between cardiovascular disease and cancer demands a fundamental shift in clinical practice. It is no longer tenable for cardiologists and oncologists to operate in silos, particularly given the ageing population and the rising prevalence of both conditions. The data presented at ESC Cardio-Oncology 2026 underscores that a patient's cancer journey cannot be divorced from their cardiovascular health, and vice versa. This necessitates early and consistent communication between specialties, ideally through integrated cardio-oncology clinics, to ensure comprehensive risk assessment and tailored treatment plans.
For the pharmaceutical industry, this evolving understanding presents both challenges and opportunities. The development of novel cancer therapies with reduced cardiotoxicity profiles will be paramount. Furthermore, there is a clear need for research into cardioprotective strategies that can be co-administered with existing effective, yet cardiotoxic, cancer treatments. Companies developing drugs in either space should consider the implications for the other, perhaps even exploring co-development or strategic partnerships to address this complex patient population more holistically. The market for supportive care in cardio-oncology is likely to expand significantly.
Ultimately, the patient experience must be at the forefront. Patients navigating a cancer diagnosis often face overwhelming information and treatment decisions. Adding the complexity of potential cardiovascular complications, or managing pre-existing heart conditions alongside cancer, can be daunting. Clinicians have a responsibility to communicate these risks clearly and to ensure that patients feel supported by a cohesive medical team. The goal is not just to extend life, but to preserve its quality, ensuring that survivors are not left with debilitating cardiovascular sequelae from their cancer treatment. This integrated approach, while requiring resource allocation, is a necessary evolution in patient-centred care.
- The Pivot The recognition of a bidirectional relationship between cardiovascular disease and cancer, moving beyond treating them as isolated conditions.
- The Data Patients with cancer have an increased risk of cardiovascular events, and conversely, patients with pre-existing CVD may experience worse cancer outcomes.
- The Action Integrated, multidisciplinary care is necessary for patients with or at risk of both conditions, involving cardiologists and oncologists from diagnosis through survivorship.
ART-2026-332
06/26
Cite This Article
Team TLSFE. Cardiovascular disease and cancer: a reciprocal relationship. The Life Science Feed. Published June 20, 2026. Updated June 20, 2026. Accessed June 20, 2026. https://thelifesciencefeed.com/cardiology/coronary-artery-disease/news/cardiovascular-disease-cancer-reciprocal-relationship.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Suter TM, Ewer MS. Cancer drugs and the heart: importance of cardiac monitoring. Eur Heart J. 2013;34(37):2949-2956. doi:10.1093/eurheartj/eht210
2. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-2801. doi:10.1093/eurheartj/ehw054
3. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Ziegelmann PK. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287-1306. doi:10.1016/j.mayocp.2014.05.013
4. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339(13):900-905. doi:10.1056/NEJM199809243391307
5. Ewer MS, Vooletich MT, Durairaj M, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights into the course of cardiac dysfunction. J Clin Oncol. 2011;29(8):1020-1026. doi:10.1200/JCO.2010.32.7855
6. Gagliardi RJ, Constine LS, Moise S, et al. Radiation-induced heart disease: a review of the literature. Int J Radiat Oncol Biol Phys. 2000;46(4):791-808. doi:10.1016/S0360-3016(99)00440-2
7. Khorana AA, Francis CW, Culakova E, Kuderer JJ, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving chemotherapy. J Thromb Haemost. 2007;5(3):632-634. doi:10.1111/j.1538-7836.2007.02374.x
8. Streiff MB, Holmstrom B, Agnelli G, et al. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018;16(11):1289-1303. doi:10.6004/jnccn.2018.0084
9. Lenihan DJ, Cardinale D, Cipolla CM, et al. The European Society of Cardiology Heart Failure Association position paper on cancer treatment and cardiotoxicity. Eur J Heart Fail. 2014;16(10):1039-1051. doi:10.1002/ejhf.147
10. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation, Immunity, and Atherothrombosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(16):2071-2083. doi:10.1016/j.jacc.2018.08.1021
11. Armenian SH, Lacchetti C, Carver J, et al. Cardiotoxicity of Cancer Therapy: An American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(29):3352-3381. doi:10.1200/JCO.2017.74.5414
12. Lancellotti P, Suter TM, Lopez-Fernandez T, et al. Cardio-Oncology: A New Frontier in Cardiovascular Medicine. Eur Heart J. 2019;40(24):1992-1999. doi:10.1093/eurheartj/ehz114
13. Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity With Enalapril and/or Carvedilol in Breast Cancer. J Clin Oncol. 2017;35(8):870-877. doi:10.1200/JCO.2016.68.5212
14. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (ICOS). Eur Heart J. 2022;43(48):4842-4973. doi:10.1093/eurheartj/ehac244
